The Company reported a net loss of 33.1 ME in the first half of 2008, compared to net loss of 6.6 ME recorded in the same period in 2007. On June 30, 2008, NicOx had cash, cash equivalents and current financial instruments and non-current amount of $ 141.6 ME 195.2 ME cons to June 30, 2007…

The clinical NicOx to the regulatory filing of naproxcinod consists of three pivotal phase 3 (studies 301, 302 and 303). Each study was designed to compare the efficacy of naproxcinod to placebo on three primary endpoints at 13 weeks.

More than half of our medicines come from plants. They are the source of treatments commonly used to treat serious diseases. But amateurs beware: they are not to be as self-medication often highly toxic. Overview of the stars of the pharmacopoeia with Editions Vidal.

The posting of 92,000 documents classified military secrecy on the conduct of the war in Afghanistan by the website Wikileaks has made the U.S. military under high pressure. At the point of forcing Obama to redefine its strategy in the area.

Side values in Paris, Sperian gets much attention (2.7% to 56.70 euros), investors greeted the sale of its apparel Cepovett Professionals, an industry expert. The specialist personal protective equipment said that the deal allows him to refocus on its core business and separate activity which does little industrial synergies, logistics or business relationship with its other businesses.



.